
|Articles|December 1, 2005
- Volume 0 0
FDA Reviews Trexima for Treatment of Migraines
Author(s)Susan Farley
Advertisement
GlaxoSmithKline and POZEN Inc announced that the drugTrexima will be reviewed by the FDA for the acute treatmentof migraine headaches. The companies have proposed Treximaas the brand name for their combination of sumatriptansuccinate (Imitrex) and naproxen sodium (Aleve, for example)in a single-tablet form. Pending approval by the FDA, Treximacould be available to the public by the second half of 2006.
Ms. Farley is a freelance medical writer based in Wakefield, RI.
Articles in this issue
over 20 years ago
CAN YOU READ THESE Rxs?over 20 years ago
Bar Coding Thwarts Illegitimate Drug Useover 20 years ago
Hypertension Counseling Requires a Multifactorial Approachover 20 years ago
COMPOUNDING HOTLINEover 20 years ago
Pharmacy Law: Duty to Warn Waived When Patient Refuses Counselingover 20 years ago
EnterpriseRx Pharmacy Management Systemover 20 years ago
Hospital Installs Automated Medication Cabinetsover 20 years ago
"Smartphones" Help with Clinical Trial Informationover 20 years ago
HIT Needs Medicare's LeadershipAdvertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacy Is a Practice, Not Just a Place
2
Beyond mRNA: A Pharmacist’s Guide to the Full COVID-19 Vaccine Landscape
3
Gemcitabine Intravesical System in Practice: Operational Considerations for Oncology Pharmacists
4
Mosunetuzumab Plus Polatuzumab Achieves Nearly 80% Complete Response Rate in Mantle Cell Lymphoma After BTK Inhibitors
5




































































































